Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Aug 092019
 

“Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

GlobeNewswire

“MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) — Geron Corporation (GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).

‘The start of the Phase 3 portion of IMerge is a significant milestone for Geron and imetelstat,’ said John A. Scarlett, M.D., Chairman and Chief Executive Officer. ‘We are hopeful that the Phase 3 will confirm the encouraging results from the Phase 2 portion, and that imetelstat could become a much-needed treatment alternative for patients with lower risk MDS.’ ”

 

 

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.  © 2019                                    The Hygiology Post ®

Click on button for instructions to purchase any product with desired cryptocurrency below and/or tip for content comprising hundreds of posts. Thank You!

 

Bytecoin (BCN) Address: 29bxUxr7wa8AzP8tvkAJqT8S8R5XTdBwHce9hwPhWx9oMRrsd5hxFsqR1uxBuKvSejTYqVXC6TSe241KoxVg1sF2SXZ6Z9H

Verge (XVG) Address: DCF3g6Zj6g3NspfNeMs6JsEgCsAVmVmkg4

MaidSafeCoin/Safecoin (MAID) Address: Rtd6RWvA1xLFhHKYCfvk5dt7UsstdFcbfK